The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Open accessAbstract
Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo-chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit for tislelizumab-chemotherapy versus placebo-chemotherapy was observed regardless of programmed death-ligand 1 expression. PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy. The safety profile was similar between arms. Gene expression profiling (GEP) identified immunologically "hot" tumors, and showed an activated dendritic cell (DC) signature was associated with tislelizumab-chemotherapy PFS benefit. Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment. VIDEO ABSTRACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302
Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00302-8 · Cited by 462
Self-citation
Cited by
Mai, H.-Q., Chen, Q.-Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y., Jin, F., Xu, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.20181 · Cited by 279
Self-citation
Metadata
- Authors
- Yang, Y., Pan, J., Wang, H., Zhao, Y., Qu, S., Chen, N., Chen, X., Sun, Y., He, X., Hu, C., Lin, L., Yu, Q., Wang, S., Wang, G., Lei, F., Wen, J., Yang, K., Lin, Z., Guo, Y., Chen, S., Huang, X., Wu, Y., Liang, L., Chen, C., Bai, F., Ma, X., Zhang, Y., Leaw, S., Zhang, L., & Fang, W.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 41
- Issue
- 6
- Pages
- 1061-1072.e4
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4377020104
- Cited by
- 237
- References
- 2
- FWCI
- 52.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). https://app.cochat.ai/papers/10.1016/j.ccell.2023.04.014
- The paper
- Yang, Y., Pan, J., Wang, H., Zhao, Y., Qu, S., Chen, N., Chen, X., Sun, Y., He, X., Hu, C., Lin, L., Yu, Q., Wang, S., Wang, G., Lei, F., Wen, J., Yang, K., Lin, Z., Guo, Y., . . . Fang, W. (2023). Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell. https://doi.org/10.1016/j.ccell.2023.04.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
